<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04967742</url>
  </required_header>
  <id_info>
    <org_study_id>V-123</org_study_id>
    <nct_id>NCT04967742</nct_id>
  </id_info>
  <brief_title>A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine</brief_title>
  <official_title>A Phase I, Open-Label Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Biomedical Inc., Asia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vaxxinity, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>United Biomedical Inc., Asia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an extension study to evaluate the safety, tolerability and immunogenicity of one&#xD;
      booster dose of UB-612 COVID-19 vaccine in adults who completed two vaccinations of UB-612&#xD;
      vaccine 10, 30, and 100 μg in V-122 study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an extension study to evaluate the safety, tolerability and immunogenicity of one&#xD;
      booster dose of UB-612 COVID-19 vaccine in adults who completed two vaccinations of UB-612&#xD;
      vaccine 10, 30, and 100 μg in V-122 study. 60 subjects will receive one booster dose of&#xD;
      UB-612 vaccines 100 μg with the same dose which was offered in Phase II study, at least 6&#xD;
      months after first vaccination. In this study, there will be 3 clinical visits. Subjects will&#xD;
      come to the clinics at Day 1, Day 15, and Day 85.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GMT of neutralizing antibody against SARS-CoV-2</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMT of neutralizing antibody against SARS-CoV-2</measure>
    <time_frame>Day 15</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMT of neutralizing antibody against SARS-CoV-2</measure>
    <time_frame>Day 85</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean fold increase of neutralizing antibody against SARS-CoV-2</measure>
    <time_frame>Day 15</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean fold increase of neutralizing antibody against SARS-CoV-2</measure>
    <time_frame>Day 85</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse reactions and the percentage of subjects with ≥ Grade 3 adverse events</measure>
    <time_frame>Within 7 days after vaccination</time_frame>
    <description>Evaluation of Safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT of antigen-specific antibody (Anti-S1-RBD)</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of antigen-specific antibody (Anti-S1-RBD)</measure>
    <time_frame>Day 15</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of antigen-specific antibody (Anti-S1-RBD)</measure>
    <time_frame>Day 85</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold increase of antigen-specific antibody (Anti-S1-RBD)</measure>
    <time_frame>Day 15</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold increase of antigen-specific antibody (Anti-S1-RBD)</measure>
    <time_frame>Day 85</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the immune response detected by ELISA and live virus neutralization test</measure>
    <time_frame>During the study period</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of SAEs, AESIs, MAAEs and SAEs</measure>
    <time_frame>During the study period</time_frame>
    <description>Evaluation of Safety</description>
  </secondary_outcome>
  <other_outcome>
    <measure>T cell responses to UB-612 COVID-19 Vaccine</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </other_outcome>
  <other_outcome>
    <measure>T cell responses to UB-612 COVID-19 Vaccine</measure>
    <time_frame>Day 15</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </other_outcome>
  <other_outcome>
    <measure>T cell responses to UB-612 COVID-19 Vaccine</measure>
    <time_frame>Day 85</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </other_outcome>
  <other_outcome>
    <measure>GMT of neutralizing antibody against SARS-CoV-2 variants</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </other_outcome>
  <other_outcome>
    <measure>GMT of neutralizing antibody against SARS-CoV-2 variants</measure>
    <time_frame>Day 15</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </other_outcome>
  <other_outcome>
    <measure>GMT of neutralizing antibody against SARS-CoV-2 variants</measure>
    <time_frame>Day 85</time_frame>
    <description>Evaluation of Immunogenicity</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID-19; SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>A group: 1 booster dose of UB-612 vaccine 100 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 booster dose for subjects at UB-612 vaccine 10 μg in V-122 study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B group: 1 booster dose of UB-612 vaccine 100 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 booster dose for subjects at UB-612 vaccine 30 μg in V-122 study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C group: 1 booster dose of UB-612 vaccine 100 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 booster dose for subjects at UB-612 vaccine 100 μg in V-122 study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-612</intervention_name>
    <description>UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.</description>
    <arm_group_label>A group: 1 booster dose of UB-612 vaccine 100 μg</arm_group_label>
    <arm_group_label>B group: 1 booster dose of UB-612 vaccine 100 μg</arm_group_label>
    <arm_group_label>C group: 1 booster dose of UB-612 vaccine 100 μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria&#xD;
&#xD;
               1. Male or non-pregnant female who previously participated in and completed two&#xD;
                  vaccinations in the V-122 Study.&#xD;
&#xD;
               2. Women of childbearing potential and men must agree to practice medically&#xD;
                  effective contraception during study period.&#xD;
&#xD;
               3. Able to understand the content and possible risks of informed consent and willing&#xD;
                  to sign the Informed Consent Form (ICF).&#xD;
&#xD;
               4. Able to understand and agrees to comply with all study procedures and be&#xD;
                  available for all study visits.&#xD;
&#xD;
               5. Ear temperature ≤ 38.0°C.&#xD;
&#xD;
               6. At screening visit, at least 6 months after first vaccination in the V-122 study.&#xD;
&#xD;
          -  Exclusion Criteria&#xD;
&#xD;
               1. Female who is pregnant or positive in pregnancy test at screening visit.&#xD;
&#xD;
               2. Female who is breast-feeding or plans to breastfeed within 90 days after booster&#xD;
                  vaccination.&#xD;
&#xD;
               3. Any acute illness, as determined by the study investigator 3 days before booster&#xD;
                  vaccination.&#xD;
&#xD;
               4. Prior administration of attenuated, nucleic acid (mRNA or DNA) or vectored&#xD;
                  vaccines in last 1 month before booster vaccination or expectation of such&#xD;
                  vaccines in the month after booster vaccination.&#xD;
&#xD;
               5. Prior administration of subunit vaccine or inactivated vaccine in last 14 days&#xD;
                  before booster vaccination or expectation of receipt of such vaccines in the 14&#xD;
                  days after booster vaccination.&#xD;
&#xD;
               6. Any medical disease or condition that, in the opinion of the study investigator,&#xD;
                  may confound the results of the study or pose an additional risk to the subjects&#xD;
                  by their participation in the study.&#xD;
&#xD;
               7. Previous exposure to SARS-CoV-2 or receipt of an investigational or EUA vaccine&#xD;
                  product for the prevention of COVID-19, MERS or SARS except UB-612.&#xD;
&#xD;
               8. Subjects who take part in another clinical study, other than V-122 study, within&#xD;
                  12 weeks prior to the day of informed consent.&#xD;
&#xD;
               9. Prior administration of immunoglobulins and/or any blood products in last 4&#xD;
                  months before booster vaccination.&#xD;
&#xD;
              10. Prior chronic administration of immunosuppressant or corticosteroids, cytotoxic&#xD;
                  treatment in last 6 months before first vaccination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang-Yi Wang, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>United Biomedical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hope Liu, Ph.D</last_name>
    <phone>+886-3-657-8861</phone>
    <phone_ext>5837</phone_ext>
    <email>hope.liu@ubiasia.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kao-Pin Hwang, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Kao-Pin Hwang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Po-Chang Lin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen-Yuan Lin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

